These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 12185557)
1. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Xu P; Huang SL; Zhu RH; Han XM; Zhou HH Eur J Clin Pharmacol; 2002 Aug; 58(5):333-7. PubMed ID: 12185557 [TBL] [Abstract][Full Text] [Related]
2. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Peamkrasatam S; Sriwatanakul K; Kiyotani K; Fujieda M; Yamazaki H; Kamataki T; Yoovathaworn K Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563 [TBL] [Abstract][Full Text] [Related]
3. Determination of coumarin metabolism in Turkish population. Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269 [TBL] [Abstract][Full Text] [Related]
4. Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity. Kharasch ED; Hankins DC; Taraday JK Drug Metab Dispos; 2000 Jan; 28(1):28-33. PubMed ID: 10611136 [TBL] [Abstract][Full Text] [Related]
5. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females. Ujjin P; Satarug S; Vanavanitkun Y; Daigo S; Ariyoshi N; Yamazaki H; Reilly PE; Moore MR; Kamataki T Pharmacogenetics; 2002 Apr; 12(3):241-9. PubMed ID: 11927840 [TBL] [Abstract][Full Text] [Related]
6. Artemisinin and CYP2A6 activity in healthy subjects. Asimus S; Hai TN; Van Huong N; Ashton M Eur J Clin Pharmacol; 2008 Mar; 64(3):283-92. PubMed ID: 18064444 [TBL] [Abstract][Full Text] [Related]
7. Effects of chronic exposure to low-level cadmium on renal tubular function and CYP2A6-mediated coumarin metabolism in healthy human subjects. Satarug S; Nishijo M; Ujjin P; Vanavanitkun Y; Baker JR; Moore MR Toxicol Lett; 2004 Mar; 148(3):187-97. PubMed ID: 15041069 [TBL] [Abstract][Full Text] [Related]
8. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans. Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041 [TBL] [Abstract][Full Text] [Related]
9. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6. Nakajima M; Kuroiwa Y; Yokoi T Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152 [TBL] [Abstract][Full Text] [Related]
10. Variability of coumarin 7- and 3-hydroxylation in a Jordanian population is suggestive of a functional polymorphism in cytochrome P450 CYP2A6. Hadidi H; Irshaid Y; Vågbø CB; Brunsvik A; Cholerton S; Zahlsen K; Idle JR Eur J Clin Pharmacol; 1998 Jul; 54(5):437-41. PubMed ID: 9754990 [TBL] [Abstract][Full Text] [Related]
11. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Rautio A; Kraul H; Kojo A; Salmela E; Pelkonen O Pharmacogenetics; 1992 Oct; 2(5):227-33. PubMed ID: 1306122 [TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Oscarson M Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795 [TBL] [Abstract][Full Text] [Related]
13. Single-dose disulfiram does not inhibit CYP2A6 activity. Kharasch ED; Hankins DC; Baxter PJ; Thummel KE Clin Pharmacol Ther; 1998 Jul; 64(1):39-45. PubMed ID: 9695717 [TBL] [Abstract][Full Text] [Related]
14. [Researches on the polymorphism of cytochrome P450 2A6]. Tong Z; ZhuGe J; Yu Y Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Oct; 19(5):424-7. PubMed ID: 12362322 [TBL] [Abstract][Full Text] [Related]
16. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137 [TBL] [Abstract][Full Text] [Related]
17. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Ring HZ; Valdes AM; Nishita DM; Prasad S; Jacob P; Tyndale RF; Swan GE; Benowitz NL Pharmacogenet Genomics; 2007 Dec; 17(12):1007-15. PubMed ID: 18004205 [TBL] [Abstract][Full Text] [Related]
18. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Haberl M; Anwald B; Klein K; Weil R; Fuss C; Gepdiremen A; Zanger UM; Meyer UA; Wojnowski L Pharmacogenet Genomics; 2005 Sep; 15(9):609-24. PubMed ID: 16041240 [TBL] [Abstract][Full Text] [Related]
19. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Hadidi H; Zahlsen K; Idle JR; Cholerton S Food Chem Toxicol; 1997 Sep; 35(9):903-7. PubMed ID: 9409631 [TBL] [Abstract][Full Text] [Related]
20. Growth hormone does not alter CYP2A6 activity in growth hormone-deficient children. Sinués B; Fanlo A; Vicente J; Mayayo-Sinués E; Mayayo E; Labarta JI; Ferrandez-Longás A Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):45-9. PubMed ID: 17927692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]